COSMOS Pharmaceutical Corporation
3349.T · JPX
5/31/2025 | 5/31/2024 | 5/31/2023 | 5/31/2022 | |
|---|---|---|---|---|
| Market Cap | ¥699,997,824 | ¥502,777,800 | ¥525,082,740 | ¥483,107,800 |
| - Cash | ¥57,038,000 | ¥52,301,000 | ¥45,928,000 | ¥37,362,000 |
| + Debt | ¥49,957,000 | ¥34,063,000 | ¥18,201,000 | ¥9,413,000 |
| Enterprise Value | ¥692,916,824 | ¥484,539,800 | ¥497,355,740 | ¥455,158,800 |
| Revenue | ¥1,011,390,000 | ¥964,989,000 | ¥827,697,000 | ¥755,414,000 |
| % Growth | 4.8% | 16.6% | 9.6% | – |
| Gross Profit | ¥213,281,000 | ¥188,306,000 | ¥168,718,000 | ¥151,448,000 |
| % Margin | 21.1% | 19.5% | 20.4% | 20% |
| EBITDA | ¥64,855,000 | ¥53,744,000 | ¥50,192,000 | ¥48,210,000 |
| % Margin | 6.4% | 5.6% | 6.1% | 6.4% |
| Net Income | ¥30,978,000 | ¥24,454,000 | ¥23,797,000 | ¥23,155,000 |
| % Margin | 3.1% | 2.5% | 2.9% | 3.1% |
| EPS Diluted | 390.85 | 308.61 | 300.48 | 292.37 |
| % Growth | 26.6% | 2.7% | 2.8% | – |
| Operating Cash Flow | ¥52,467,000 | ¥52,467,000 | ¥55,175,000 | ¥54,434,000 |
| Capital Expenditures | -¥53,326,000 | -¥53,326,000 | -¥55,810,000 | -¥46,636,000 |
| Free Cash Flow | -¥859,000 | -¥859,000 | -¥635,000 | ¥7,798,000 |